



ZIOPHARM Oncology, Inc.
 Investor Relations Department
 One First Ave., Parris Building, # 34
 Navy Yard Plaza
 Boston, MA 02199
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	5.75
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	0.04 (+0.701%)
Day Range	5.62 - 5.82
52-Week Range	4.94 - 7.88
Volume	958,452


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 16, 2017*
[ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors](#)
- Oct 12, 2017*
[ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)
- Sep 28, 2017*
[ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer](#)
- Sep 18, 2017*
[ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting](#)
- Sep 5, 2017*
[ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

Financials [\[View all \]](#)

- Feb 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Jul 31, 2017*
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*
[Quarterly Report \(10-Q\)](#)